4.8 Editorial Material

Why is it hard to terminate failing projects in pharmaceutical R&D?

期刊

NATURE REVIEWS DRUG DISCOVERY
卷 14, 期 10, 页码 663-664

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/nrd4725

关键词

-

向作者/读者索取更多资源

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Rheumatology

EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases

Charlotte L. M. Krieckaert, Astrid van Tubergen, Johanna Elin Gehin, Borja Hernandez-Breijo, Guillaume Le Meledo, Alejandro Balsa, Peter Boehm, Sasa Cucnik, Ori Elkayam, Guro L. Goll, Femke Hooijberg, Meghna Jani, Patrick D. W. Kiely, Neil McCarthy, Denis Mulleman, Victoria Navarro-Compan, Katherine Payne, Martin E. Perry, Chamaida Plasencia-Rodriguez, Simon R. Stones, Silje Watterdal Syversen, Annick de Vries, Katherine M. Ward, Gertjan Wolbink, John D. Isaacs

Summary: This study develops EULAR points-to-consider for therapeutic drug monitoring (TDM) of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases (RMDs). The points-to-consider are evidence-based and consensus-based statements that highlight the clinical utility of TDM. However, the lack of high quality trials addressing effectiveness and safety of TDM, as well as robust economic evaluation, limits its wider adoption.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Pre-defined gene co-expression modules in rheumatoid arthritis transition towards molecular health following anti-TNF therapy

Megan Sutcliffe, Nisha Nair, James Oliver, Ann W. Morgan, John D. Isaacs, Anthony G. Wilson, Suzanne M. M. Verstappen, Sebastien Viatte, Kimme L. Hyrich, Andrew P. Morris, Anne Barton, Darren Plant

Summary: This study validates changes in module expression in response to therapy in RA and identifies modules that transition towards a disease-free state. However, these effects are not specific to TNFi therapy.

RHEUMATOLOGY (2022)

Article Rheumatology

The role of comorbidities alongside patient and disease characteristics in long-term disease activity in RA using UK inception cohort data

Amanda D. Busby, James Wason, Arthur G. Pratt, Adam Young, John D. Isaacs, Elena Nikiphorou

Summary: This study identifies an association between sociodemographic and clinical factors and long-term disease activity in rheumatoid arthritis (RA), highlighting the need for more holistic and targeted patient management, even at the first presentation to rheumatology.

RHEUMATOLOGY (2022)

Article Multidisciplinary Sciences

RA-MAP, molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipients

John D. Isaacs, Sarah Brockbank, Ayako Wakatsuki Pedersen, Catharien Hilkens, Amy Anderson, Philip Stocks, Dennis Lendrem, Jessica Tarn, Graham R. Smith, Ben Allen, John Casement, Julie Diboll, Rachel Harry, Faye A. H. Cooles, Andrew P. Cope, Gemma Simpson, Ruth Toward, Hayley Noble, Angela Parke, Wing Wu, Fiona Clarke, David Scott, Ian C. Scott, James Galloway, Heidi Lempp, Fowzia Ibrahim, Samana Schwank, Gemma Molyneux, Tomi Lazarov, Frederic Geissmann, Carl S. Goodyear, Iain B. McInnes, Iona Donnelly, Ashley Gilmour, Aysin Tulunay Virlan, Duncan Porter, Frederique Ponchel, Paul Emery, Jehan El-Jawhari, Rekha Parmar, Michael F. McDermott, Benjamin A. Fisher, Steve P. Young, Philip Jones, Karim Raza, Andrew Filer, Costantino Pitzalis, Michael R. Barnes, David S. Watson, Rafael Henkin, Georgina Thorborn, Liliane Fossati-Jimack, Stephen Kelly, Frances Humby, Michele Bombardieri, Sharmila Rana, Zhilong Jia, Katriona Goldmann, Myles Lewis, Sandra Ng, Adriano Barbosa-Silva, Evan Tzanis, Amaya Gallagher-Syed, Christopher R. John, Michael R. Ehrenstein, Gioia Altobelli, Sandra Martins, Dao Nguyen, Humayara Ali, Coziana Ciurtin, Maya Buch, Deborah Symmons, Jane Worthington, Ian N. Bruce, Jamie C. Sergeant, Suzanne M. M. Verstappen, Fiona Stirling, Adwoa Hughes-Morley, Brian Tom, Vernon Farewell, Yujie Zhong, Peter C. Taylor, Christopher D. Buckley, Sarah Keidel, Carolyn Cuff, Marc Levesque, Andrew Long, Zheng Liu, Samantha Lipsky, Bohdan Harvey, Michael Macoritto, Feng Hong, Sukru Kaymakcalan, Wayne Tsuji, Tony Sabin, Neil Ward, Susan Talbot, Desmond Padhji, Matthew Sleeman, Donna Finch, Athula Herath, Catharina Lindholm, Martin Jenkins, Meilien Ho, Sally Hollis, Chris Marshall, Gerry Parker, Matt Page, Hannah Edwards, Alexandru Cuza, Neil Gozzard, Ioannis Pandis, Anthony Rowe, Francisco Bonachela Capdevila, Matthew J. Loza, Mark Curran, Denny Verbeeck, Dan Baker, Christopher M. Mela, Ivana Vranic, Catherine T. Mela, Stephen Wright, Lucy Rowell, Emma Vernon, Nina Joseph, Neil Payne, Ravi Rao, Michael Binks, Alexandra Belson, Valerie Ludbrook, Kirsty Hicks, Hannah Tipney, Joanne Ellis, Samiul Hasan, Arnaud Didierlaurent, Wivine Burny, Andrea Haynes, Chris Larminie, Ray Harris, Daniela Dastros-Pitei, Claudio Carini, Blerina Kola, Scott Jelinsky, Martin Hodge, Mateusz Maciejewski, Daniel Ziemek, Peter Schulz-Knappe, Hans-Dieter Zucht, Petra Budde, Mark Coles, James A. Butler, Simon Read

Summary: This study conducted comprehensive clinical and molecular profiling of early, drug naive RA patients, establishing a high-quality sample biobank and performing multi-omic immune phenotyping. The data obtained is expected to provide important insights into the pathogenesis, progression, and therapeutic response of RA.

SCIENTIFIC DATA (2022)

Article Rheumatology

Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update

Daniel Aletaha, Andreas Kerschbaumer, Kastriot Kastrati, Christian Dejaco, Maxime Dougados, Iain B. McInnes, Naveed Sattar, Tanja A. Stamm, Tsutomu Takeuchi, Michael Trauner, Desiree van der Heijde, Marieke Voshaar, Kevin L. Winthrop, Angelo Ravelli, Neil Betteridge, Gerd-Ruediger R. Burmester, Johannes W. J. Bijlsma, Vivian Bykerk, Roberto Caporali, Ernest H. Choy, Catalin Codreanu, Bernard Combe, Mary K. Crow, Maarten de Wit, Paul Emery, Roy M. Fleischmann, Cem Gabay, Merete Lund Hetland, Kimme L. Hyrich, Annamaria Iagnocco, John D. Isaacs, Joel M. Kremer, Xavier Mariette, Peter Merkel, Eduardo F. Mysler, Peter Nash, Michael T. Nurmohamed, Karel Pavelka, Gyula Poor, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Anja Strangfeld, Yoshiya Tanaka, Josef S. Smolen

Summary: This paper is an updated consensus document on the medical use of IL-6 pathway inhibition in the treatment of inflammatory diseases. The document provides comprehensive consensus statements based on systematic literature research and expert opinion, covering various aspects of IL-6 pathway inhibitors, including dosing, indications, and clinical considerations.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Immunology

Characterization of age-associated B cells in early drug-naive rheumatoid arthritis patients

Gemma Vidal-Pedrola, Najib Naamane, James A. Cameron, Arthur G. Pratt, Andrew L. Mellor, John D. Isaacs, Dagmar Scheel-Toellner, Amy E. Anderson

Summary: Age-associated B cells (ABCs) are an immune cell subset linked to autoimmunity, infection, and aging. Studies have shown that ABCs in the peripheral blood of patients with early rheumatoid arthritis (eRA) exhibit distinct transcriptional characteristics compared to control groups, and they are found to be abundant in synovial fluid. These activated B cells express chemokine receptors and adhesion molecules that favor inflammation over lymphoid tissue, and they may play a role in autoimmune pathology due to their antigen presentation and pro-inflammatory phenotype.

IMMUNOLOGY (2023)

Article Rheumatology

Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis

Ryan M. Hum, Pauline Ho, Nisha Nair, Meghna Jani, Ann W. Morgan, John D. Isaacs, Anthony G. Wilson, Kimme L. Hyrich, Darren Plant, Anne Barton

Summary: This study suggests that higher levels of TNF-a inhibitor serum drug levels (SDLs) are associated with good treatment response in fully adherent patients. Interventions to improve SDLs, such as encouraging adherence, may improve treatment response. The identified SDL cut-offs for adalimumab and certolizumab may be useful in clinical practice.

RHEUMATOLOGY (2023)

Review Rheumatology

Opportunistic infections associated with Janus kinase inhibitor treatment for rheumatoid arthritis: A structured literature review

Kevin Winthrop, John Isaacs, Leonard Calabrese, Deepali Mittal, Supriya Desai, Jane Barry, Sander Strengholt, James Galloway

Summary: A literature review of clinical trials found that the use of JAK inhibitors for rheumatoid arthritis is associated with opportunistic infections, with herpes zoster being the most common. Higher rates of infections were observed in Asian and Australian populations, as well as with increasing doses of JAK inhibitors.

SEMINARS IN ARTHRITIS AND RHEUMATISM (2023)

Article Rheumatology

Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022

Kevin L. Winthrop, John D. Isaacs, Philip J. Mease, Dimitrios T. Boumpas, Xenofon Baraliakos, Jacques-Eric Gottenberg, Stefan Siebert, Marta Mosca, Neil Basu, Dana Orange, R. Lories, Daniel Aletaha, Iain B. McInnes, Tom W. J. Huizinga, Reinhard E. Voll, Ellen M. Gravallese, Ferry C. Breedveld, Josef S. Smolen

Summary: This article summarizes the unmet clinical and scientific needs in the field of rheumatology. It highlights the importance of clinical trial design innovation and the need to better understand the natural history of rheumatic diseases. The article also identifies the specific unmet needs in different rheumatological disease-specific groups and emphasizes the importance of developing therapies and therapeutic strategies for treatment-refractory disease.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis

Samantha Louise Smith, Sheree Alexander, Nisha Nair, Sebastien Viatte, Stephen Eyre, Kimme L. Hyrich, Ann W. Morgan, Anthony G. Wilson, John D. Isaacs, Darren Plant, Anne Barton

Summary: The study aimed to explore whether the inflammatory protein MRP8/14 can serve as a biomarker for treatment response in rheumatoid arthritis (RA) patients receiving tumor necrosis factor (TNF) inhibitors. The results showed that in the 3-component and 2-component models, patients with high pre-treatment levels of MRP8/14 were 1.92 and 2.03 times more likely to be classified as EULAR responders compared to those with low levels. However, no significant associations were observed in the 4-component model. Conclusion: Apart from its correlation with CRP, there is no evidence to suggest that MRP8/14 explains additional variability in response to TNFi in RA patients beyond CRP alone.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Letter Biophysics

Host versus graft HLA-DP1 mismatching promotes graft versus host disease

Callum Wright, Ginette Reid, Beverley Clare Lendrem, Erin Hurst, Amy Publicover, Rachel Luke, Louise Duncan, Venetia Bigley, Matthew Collin

BONE MARROW TRANSPLANTATION (2023)

Letter Rheumatology

The Effect of COVID-19 on Medication Adherence in a Rheumatoid Arthritis (BRAGGSS) and Psoriatic Arthritis (OUTPASS) UK Cohort

Philippa D. K. Curry, Hector Chinoy, Meghna Jani, Darren Plant, Kimmie L. Hyrich, Ann W. Morgan, A. G. Wilson, John D. Isaacs, Andrew P. Morris, Anne Barton, James Bluett

JOURNAL OF RHEUMATOLOGY (2023)

Article Urology & Nephrology

Coping strategies, illness perceptions, and relationship dynamics contribute to female sexual function and sexual distress in Sjogren's syndrome

Jemma L. McCready, Vincent Deary, Tracy L. Collins, Dennis W. Lendrem, Katie L. Hackett

Summary: This study investigated the role of psychosocial and interpersonal factors in sexual function and distress for women with Sjogren's syndrome. The findings showed that coping strategies, illness perceptions, and relationship dynamics were all significant contributors to sexual function and distress in this population.

JOURNAL OF SEXUAL MEDICINE (2023)

Review Rheumatology

Rheumatoid sarcopenia: loss of skeletal muscle strength and mass in rheumatoid arthritis

Joshua. L. L. Bennett, Arthur. G. G. Pratt, Richard Dodds, Avan. A. A. Sayer, John. D. D. Isaacs

Summary: Sarcopenia, characterized by the loss of skeletal muscle strength and mass, is commonly associated with rheumatoid arthritis. This review discusses the epidemiology, pathophysiology, and identification of rheumatoid sarcopenia, as well as the therapeutic roles of physical activity, nutrition, and pharmacotherapy. Rheumatoid sarcopenia is highly prevalent (>= 25%) in individuals with rheumatoid arthritis and is associated with increased risk of falls, fractures, and physical disability.

NATURE REVIEWS RHEUMATOLOGY (2023)

Article Rheumatology

Number of days required to measure sedentary time and physical activity using accelerometery in rheumatoid arthritis: a reliability study

Ciara D. O'Brien, George Kitas, Fiona D. Rayner, John F. Isaacs, Kenneth G. Baker, Arthur D. Pratt, Christopher Buckley, Karim Raza, Andrew Filer, Stefan Siebert, Iain McInnes, Andrew McGucken, Sally A. M. Fenton, BIOFLARE Consortium

Summary: This study aimed to determine the minimum number of monitoring days required to reliably estimate sedentary time, light-intensity physical activity, and moderate-intensity physical activity in people with Rheumatoid Arthritis (RA) across different levels of disease activity. The results showed that at least 4 monitoring days were required to reliably estimate sedentary time and light-intensity physical activity, while at least 5 monitoring days were required to reliably estimate behaviors across the movement continuum. This information is important for accurately assessing physical activity levels and sedentary behavior in RA patients and can help inform interventions for promoting physical activity and reducing sedentary time.

RHEUMATOLOGY INTERNATIONAL (2023)

暂无数据